Avacincaptad pegol sodium

Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD) . Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system. Avacincaptad pegol sodium treats Geographic atrophy (GA) mice[1][2][3][4].

Product Specifications

CAS Number

[1491144-00-3]

Product Name Alternative

ARC1905

UNSPSC

12352208

Target

Complement System

Type

Oligonucleotides

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/avacincaptad-pegol-sodium.html

Purity

94.64

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

[Avacincaptadpegolsodium]

Molecular Formula

C395H453F21N142Na39O262P39 (C2H4O) 2n

Molecular Weight

53500 (Approximately)

References & Citations

[1]Joshua Ong, et al. The Complement System as a Therapeutic Target in Retinal Disease. Medicina (Kaunas) . 2024 Jun 5;60 (6) :945.|[2]Yiming Li, et al. Targeting both C5 and HTRA1 provides additional rescue effect in NaIO3-induce GA model. IOVS. June 2024, Vol.65, OD68.|[3]Aira Sarkar, et al. Novel and investigational therapies for wet and dry age-related macular degeneration. Drug Discov Today. 2022 Aug;27 (8) :2322-2332.|[4]Padma Sundaram, et al. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013 Jan 23;48 (1-2) :259-71.|[5]Thomas Ryan Jarrett, et al. Material Trends and Clinical Costings in Systematically Identified CDER-Approved Nanomedicines. Advanced Therapeutics. 02 September 2024.